Do Infectious Diseases After Kidney Retransplantation Differ From Those After First Kidney Transplantation?
infections
kidney retransplantation
organ allocation
Journal
Open forum infectious diseases
ISSN: 2328-8957
Titre abrégé: Open Forum Infect Dis
Pays: United States
ID NLM: 101637045
Informations de publication
Date de publication:
Mar 2024
Mar 2024
Historique:
received:
17
09
2023
accepted:
29
01
2024
medline:
11
3
2024
pubmed:
11
3
2024
entrez:
11
3
2024
Statut:
epublish
Résumé
Infectious diseases (IDs) are highly relevant after solid organ transplantation in terms of morbidity and mortality, being among the most common causes of death. Patients undergoing kidney retransplantation (re-K-Tx) have been already receiving immunosuppressive therapy over a prolonged period, potentially facilitating subsequent infections. Comparing ID events after re-K-Tx and first kidney transplantation (f-K-Tx) can delineate patterns and risks of ID events associated with prolonged immunosuppression. We included adult patients with records on f-K-Tx and re-K-Tx in the Swiss Transplant Cohort Study. We analyzed ID events after f-K-Tx and re-K-Tx within the same patients and compared infection rates, causative pathogens, and infection sites. Recurrent time-to-event analyses were performed for comparison of infection rates. A total of 59 patients with a median age of 47 years (range, 18-73) were included. Overall, 312 ID events in 52 patients occurred. In multivariable recurrent event modeling, the rate of ID events was significantly lower after re-K-Tx (hazard ratio, 0.70; ID events were less frequent after re-K-Tx. Affected sites differed significantly after f-K-Tx vs re-K-Tx.
Sections du résumé
Background
UNASSIGNED
Infectious diseases (IDs) are highly relevant after solid organ transplantation in terms of morbidity and mortality, being among the most common causes of death. Patients undergoing kidney retransplantation (re-K-Tx) have been already receiving immunosuppressive therapy over a prolonged period, potentially facilitating subsequent infections. Comparing ID events after re-K-Tx and first kidney transplantation (f-K-Tx) can delineate patterns and risks of ID events associated with prolonged immunosuppression.
Methods
UNASSIGNED
We included adult patients with records on f-K-Tx and re-K-Tx in the Swiss Transplant Cohort Study. We analyzed ID events after f-K-Tx and re-K-Tx within the same patients and compared infection rates, causative pathogens, and infection sites. Recurrent time-to-event analyses were performed for comparison of infection rates.
Results
UNASSIGNED
A total of 59 patients with a median age of 47 years (range, 18-73) were included. Overall, 312 ID events in 52 patients occurred. In multivariable recurrent event modeling, the rate of ID events was significantly lower after re-K-Tx (hazard ratio, 0.70;
Conclusions
UNASSIGNED
ID events were less frequent after re-K-Tx. Affected sites differed significantly after f-K-Tx vs re-K-Tx.
Identifiants
pubmed: 38464489
doi: 10.1093/ofid/ofae055
pii: ofae055
pmc: PMC10923290
doi:
Types de publication
Journal Article
Langues
eng
Pagination
ofae055Investigateurs
P Amico
(P)
J-D Aubert
(JD)
V Banz
(V)
S Beckmann
(S)
G Beldi
(G)
C Berger
(C)
E Berishvili
(E)
A Berzigotti
(A)
I Binet
(I)
P-Y Bochud
(PY)
S Branca
(S)
H Bucher
(H)
E Catana
(E)
A Cairoli
(A)
Y Chalandon
(Y)
S De Geest
(S)
O De Rougemont
(O)
S De Seigneux
(S)
M Dickenmann
(M)
J L Dreifuss
(JL)
M Duchosal
(M)
T Fehr
(T)
S Ferrari-Lacraz
(S)
C Garzoni
(C)
D Golshayan
(D)
N Goossens
(N)
F H J Halter
(FHJ)
D Heim
(D)
C Hess
(C)
S Hillinger
(S)
H H Hirsch
(HH)
P Hirt
(P)
G Hofbauer
(G)
U Huynh-Do
(U)
F Immer
(F)
M Koller
(M)
M Laager
(M)
B Laesser
(B)
F Lamoth
(F)
R Lehmann
(R)
A Leichtle
(A)
O Manuel
(O)
H P Marti
(HP)
M Martinelli
(M)
V McLin
(V)
K Mellac
(K)
A Merçay
(A)
K Mettler
(K)
A Müller
(A)
N J Mueller
(NJ)
U Müller-Arndt
(U)
B Müllhaupt
(B)
M Nägeli
(M)
G Oldani
(G)
M Pascual
(M)
J Passweg
(J)
R Pazeller
(R)
K Posfay-Barbe
(K)
J Rick
(J)
A Rosselet
(A)
S Rossi
(S)
S Rothlin
(S)
F Ruschitzka
(F)
T Schachtner
(T)
U Schanz
(U)
S Schaub
(S)
A Scherrer
(A)
A Schnyder
(A)
M Schuurmans
(M)
S Schwab
(S)
T Sengstag
(T)
F Simonetta
(F)
S Stampf
(S)
J Steiger
(J)
G Stirnimann
(G)
U Stürzinger
(U)
C Van Delden
(C)
J-P Venetz
(JP)
J Villard
(J)
J Vionnet
(J)
M Wick
(M)
M Wilhelm
(M)
P Yerly
(P)
Informations de copyright
© The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
Déclaration de conflit d'intérêts
Potential conflicts of interest. P. W. S. received travel grants from Pfizer and Gilead, speaker's honorary from Pfizer, and fees for advisory board activity from Pfizer and Gilead outside the submitted work. All other authors report no potential conflicts.